KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Payables: 2009-2024

Historic Payables for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $10.2 million.

  • Halozyme Therapeutics' Payables rose 23.89% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 21.53%. This contributed to the annual value of $10.2 million for FY2024, which is 13.26% down from last year.
  • As of FY2024, Halozyme Therapeutics' Payables stood at $10.2 million, which was down 13.26% from $11.8 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Payables registered a high of $17.7 million during FY2022, and its lowest value of $1.5 million during FY2021.
  • For the 3-year period, Halozyme Therapeutics' Payables averaged around $13.3 million, with its median value being $11.8 million (2023).
  • Its Payables has fluctuated over the past 5 years, first tumbled by 70.03% in 2020, then skyrocketed by 1,048.15% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Payables (Yearly) stood at $1.9 million in 2020, then fell by 20.07% to $1.5 million in 2021, then soared by 1,048.15% to $17.7 million in 2022, then slumped by 33.22% to $11.8 million in 2023, then declined by 13.26% to $10.2 million in 2024.